UBTECH vs. Unitree: Same RMB 1B Revenue, Opposite Profit Trajectories
Same top line, opposite trajectories: UBTECH and Unitree Robotics each crossed RMB 1 billion in first-half 2026 revenue, but a RMB 581 million operating profit gap exposes fundamentally different bets on how to win China's embodied-AI race.
The simultaneous arrival of their interim results — Unitree's disclosed alongside its August 19 STAR Market debut, UBTECH's filed on August 28 — handed analysts a rare controlled comparison. Both companies now report humanoid robotics as their primary revenue driver. Both face the same industrial deployment bottleneck. Yet their income statements are moving in opposite directions across every key margin metric, a divergence that tells investors far more than the headline revenue figures alone.
Markets have already rendered a preliminary verdict. Unitree (688836.SH) closed August 28 at RMB 585 per share, implying a market capitalization of RMB 236.6 billion (US$32.9 billion). UBTECH (9880.HK) closed the same session at HK$83.50, valuing the Hong Kong-listed company at approximately HK$42 billion (RMB ~36.4 billion, or US$5.1 billion) — a valuation gap exceeding six times on revenues separated by just RMB 1.17 billion.
UBTECH's Cost Dilution Signals an Approaching Inflection Point
UBTECH posted H1 2026 revenue of RMB 1.269 billion (US$176.3 million), up 104.2% year-on-year — its first half-year result to breach the RMB 1 billion threshold since listing on the Hong Kong Stock Exchange in late 2023. The headline growth rate, however, requires adjustment. In April 2026, UBTECH completed the consolidation of Fenlong Electric, contributing RMB 139 million in lawn machinery and hydraulic components revenue, or roughly 11% of the total. Strip that out, and organic growth in the company's core robotics business runs closer to 82% — still substantial, but a more accurate baseline for comparison.
The structural story within that organic growth is more compelling. Revenue from full-size embodied-intelligence humanoid robots surged to RMB 590 million (US$81.9 million) from RMB 38.21 million in the year-earlier period — a 1,445% increase — as unit shipments jumped from approximately 45 to 921. That single product line added RMB 552 million in incremental revenue and now accounts for 46.5% of total sales, up from 6.1% a year ago.
The product-mix shift is directly rewiring the income statement. Blended gross margin expanded 9.7 percentage points to 44.7%, driven by the humanoid segment's 66.8% gross margin — which alone contributed approximately 70% of UBTECH's total gross profit of RMB 567 million. Meanwhile, absolute spending on research and development rose 38.9% year-on-year to RMB 303 million, and selling expenses grew 6.5% to RMB 238 million — but both grew far slower than revenue, compressing the R&D expense ratio from 35.1% to 23.9% and the selling expense ratio from 36.0% to 18.8%. The administrative expense ratio fell from 29.8% to 11.8%.
The result: UBTECH's operating loss narrowed 36.4% to RMB 279 million, and net loss contracted 23% to RMB 339 million. The company is not yet profitable, but the direction of travel is unambiguous. Adjusted EBITDA improved to negative RMB 174 million, a 45.9% reduction in losses.
The balance sheet introduces a countervailing concern. Accounts receivable net of provisions rose to RMB 1.680 billion at June 30 from RMB 1.302 billion at year-end 2025 — a 29% increase. Inventories climbed 71% over the same period to RMB 985 million. The largest single customer contributed RMB 309 million, or 24% of total revenue, reflecting UBTECH's concentration in large industrial and B2B project contracts with extended settlement cycles. Whether that inventory converts to recognized revenue — and whether those receivables convert to cash — will be the central question in the second-half 2026 results.
Unitree Deploys Its Profit Cushion Into R&D and Brand, Compressing Near-Term Returns
Unitree's H1 2026 figures present the mirror image. Revenue reached RMB 1.152 billion (US$160 million), up 48.54% year-on-year, and reported net profit attributable to shareholders was RMB 274 million — making Unitree the only publicly listed humanoid robotics company in China currently generating positive bottom-line earnings.
That reported profit figure, however, is inflated by a base-period distortion. In H1 2025, Unitree recognized RMB 349 million in non-recurring share-based payment expenses tied to pre-IPO employee equity arrangements, which drove the year-earlier period into a net loss of RMB 32 million. Stripping out non-recurring items from both periods, Unitree's adjusted net profit fell 19.34% year-on-year to RMB 244 million (US$33.9 million). Revenue grew 48.5%; core earnings shrank nearly a fifth. The divergence has a single cause: deliberate, aggressive reinvestment.
R&D expenditure reached RMB 136 million in H1 2026, up approximately 152% year-on-year, lifting the R&D expense ratio from 6.9% to 11.8%. Selling expenses surged roughly 250% to RMB 164 million — the company cites CCTV Spring Festival Gala sponsorship and a significant expansion of its sales headcount — pushing the selling expense ratio from approximately 6.0% to 14.2%. Combined, R&D and selling costs totalled approximately RMB 300 million in the first half, versus roughly RMB 101 million in the prior-year period, nearly a threefold increase.
The spending acceleration is also pressuring gross margin. Unitree's blended gross margin dipped approximately 4.2 percentage points to 56.0% — still 11.3 percentage points above UBTECH's 44.7%, but a reversal of the multi-year expansion trend that saw gross margin climb from 44.75% in 2023 to 57.22% in 2024 and 60.44% in 2025. Unitree attributes the prior improvement to full-stack vertical integration, scale-driven procurement leverage, and a richer product mix. The current compression reflects both the cost of that new investment and a product-mix shift as humanoid robots — which in 2025 surpassed quadruped robots to become Unitree's largest revenue segment at RMB 868 million — continue to scale.
A strategically significant capital allocation decision accompanied the IPO: DeepSeek invested approximately RMB 141 million (US$19.6 million) in Unitree's strategic placement, receiving 933,400 shares subject to a 36-month lock-up. The partnership formalizes Unitree's pivot toward large embodied-AI models, directly addressing what analysts have identified as the company's relative underinvestment in software intelligence relative to hardware efficiency.
Inventory and receivables dynamics mirror UBTECH's, though at different absolute levels. Unitree's inventories rose approximately 82% from year-end 2025 to RMB 671 million, while accounts receivable more than doubled to RMB 120 million from RMB 58.73 million.
Diverging Metrics Reflect Two Distinct Theories of Competitive Advantage
Placing the two companies side by side, the directional divergence across three core operating metrics is striking. UBTECH's gross margin is rising while its R&D and selling expense ratios fall; Unitree's gross margin is falling while its R&D and selling expense ratios rise. A year ago, Unitree held a gross margin above 60% with single-digit expense ratios, while UBTECH operated at roughly 35% gross margin with both expense ratios exceeding 30%. Today, the absolute gaps remain — Unitree's gross margin leads by more than 11 percentage points, and UBTECH's R&D expense ratio remains nearly double Unitree's — but the trajectories have crossed.
The underlying business logic differs accordingly. UBTECH's improving economics are largely a function of operating leverage: costs did not shrink, but revenue scaled faster, diluting fixed and semi-fixed expense loads. The company's partnership with Siemens on a high-capacity smart manufacturing facility — commissioned in August 2026 with a stated capacity target of 10,000 units — is designed to extend that leverage into H2 2026 and beyond. Customer coverage now spans aerospace manufacturing, automotive, consumer electronics, and smart logistics.
Unitree's trajectory reflects a deliberate choice to monetize its current profitability advantage into market position. Having demonstrated that humanoid robots can be manufactured at scale and sold at margins, it is now investing those margins into the software and brand infrastructure — embodied large models, motion control algorithms, marketing reach — that could sustain defensibility as competitors close the hardware gap.
Unitree founder Wang Xingxing offered a candid assessment at the World Robot Conference in August 2026: the "ChatGPT moment" for embodied intelligence has not yet arrived, and robots are not yet ready for broad factory deployment due to insufficient efficiency and generalization capability. His timeline estimate: two to three years in an optimistic scenario, five to ten years in a conservative one. That admission is simultaneously a risk disclosure and a strategic rationale — if the commercial inflection is still years away, the company with the strongest balance sheet and the most mature AI stack at the moment of industry takeoff wins, regardless of who leads on revenue today.
Valuation Gap Reflects Market Structure, Not Just Fundamentals
The six-times market capitalization differential demands contextual interpretation. Unitree listed on the STAR Market — China's technology-focused exchange — at a price-to-earnings multiple of 219.23 times, opened its first trading day at RMB 1,100 per share (a 629% premium to the RMB 150.80 IPO price), and briefly reached a market capitalization of RMB 444.9 billion before correcting. At the August 28 close, freely tradeable shares represented only approximately 7.44% of total shares outstanding, meaning price discovery remains constrained by limited float.
UBTECH trades on the Hong Kong Stock Exchange, where liquidity conditions, investor base composition, and risk appetite differ materially from the STAR Market. A direct market-cap multiple comparison between the two listings would be methodologically unsound.
What the valuation gap does reflect is the premium the A-share market assigns to a rare combination of profitability, full-stack vertical integration, and scarcity value in the embodied-AI category. Whether that premium is sustainable depends on whether Unitree can maintain its gross margin advantage as it scales R&D and sales investment — and whether UBTECH can convert its growing receivables and inventory into cash before its balance sheet requires additional financing.
The next set of annual results will be more revealing than any interim comparison. The questions investors should be tracking: Can UBTECH sustain its expense-ratio compression as the humanoid robot revenue base matures? Can Unitree hold a gross margin above 50% while tripling its combined R&D and selling spend? And for both companies — can the inventory accumulating on their balance sheets clear fast enough to fund the next phase of growth without external capital?
At RMB 1 billion in half-year revenue, China's humanoid robot leaders have graduated from the product-demo phase to the financial-discipline phase. The income statement, not the spec sheet, is now the primary competitive battleground.
Related Coverage:
Unitree’s Falling Floor Is Becoming a Ceiling for China’s Robot Startups
UBTECH’s U1 Bet: Record Pre-Orders, Cash Burn and the Conversion Challenge